Applications:  Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphatefrom the myometrial cell membrane. Atosiban is useful in improving the pregnancy outcome of in vitro fertilization-embryo transfer (IVF-ET) in patients with repeated implantation failure (RIF). The pregnancy rate improved from zero to 43.7%.  Applications:  Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphatefrom the myometrial cell membrane. Atosiban is useful in improving the pregnancy outcome of in vitro fertilization-embryo transfer (IVF-ET) in patients with repeated implantation failure (RIF). The pregnancy rate improved from zero to 43.7%. Â
Â
Product Name:
Atosiban
Synonyms:
1-deamino-2d-tyr-(oet)-4-thr-8-orn-oxytocin;oxytocin,1-(3-mercaptopropanoicacid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l;rwj22164;ATOSIBAN ACETATE;1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-thre onine-8-L-ornithineoxytocin;[Mpr-D-Tyr(OEt)-Ile-Thr-Asn-Cys]-Pro-Orn-Gly-NH2;(2S)-N-[(1S)-4-Amino-1-(carbamoylmethylcarbamoyl)butyl]-1-[(4S,7S,13S,16R)-13-[(2S)-butan-2-yl]-7-(carbamoylmethyl)-16-[(4-ethoxyphenyl)methyl]-10-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin
CAS:
90779-69-4
MF:
C45H71N11O14S2
MW:
994.19
EINECS:
---
Product Categories:
Peptide;hormones
Purity:
98%.99%
Contact us:
Maria
Â
Â
Â
High Quality Atosiban Acetate, Atosiban Acetate Powder
Â
Product Name:
Atosiban
Synonyms:
1-deamino-2d-tyr-(oet)-4-thr-8-orn-oxytocin;oxytocin,1-(3-mercaptopropanoicacid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l;rwj22164;ATOSIBAN ACETATE;1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-thre onine-8-L-ornithineoxytocin;[Mpr-D-Tyr(OEt)-Ile-Thr-Asn-Cys]-Pro-Orn-Gly-NH2;(2S)-N-[(1S)-4-Amino-1-(carbamoylmethylcarbamoyl)butyl]-1-[(4S,7S,13S,16R)-13-[(2S)-butan-2-yl]-7-(carbamoylmethyl)-16-[(4-ethoxyphenyl)methyl]-10-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin
CAS:
90779-69-4
MF:
C45H71N11O14S2
MW:
994.19
EINECS:
---
Product Categories:
Peptide;hormones
Purity:
98%.99%
Contact us:
Maria
Â
Â
Â
High Quality Atosiban Acetate, Atosiban Acetate Powder
Certificate: GMP
Supply Ability: 500000kg/Year
Appearence: White Powder
Packing: Plastic Tube
Trademark: FILTER
Transport Package: Plastic Tube/Vial
Specification: 2mg/vial
Origin: Shanghai
HS Code: 3003901000
Certificate: GMP
Supply Ability: 500000kg/Year
Appearence: White Powder
Packing: Plastic Tube
Trademark: FILTER
Transport Package: Plastic Tube/Vial
Specification: 2mg/vial
Origin: Shanghai
HS Code: 3003901000
High Quality Atosiban Acetate, Atosiban Acetate PowderAtosiban (trade names Tractocile, Antocin, atosiban SUN) is an inhibitor of the hormones oxytocinand vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to haltpremature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. It was developed by Ferring Pharmaceuticalsin Sweden and first reported in the literature in 1985.Originally marketed by Ferring Pharmaceuticals, it is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women
Â
Atosiban (trade names Tractocile, Antocin, atosiban SUN) is an inhibitor of the hormones oxytocinand vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to haltpremature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. It was developed by Ferring Pharmaceuticalsin Sweden and first reported in the literature in 1985.Originally marketed by Ferring Pharmaceuticals, it is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women
Â